Evaluation of cell-penetrating peptide/adenovirus particles for transduction of CAR-negative cells

Journal of Pharmaceutical Sciences

Volumn 102, Issue 6, 2013, Pages 1981-1993

  Nigatu, Adane S ^a   Vupputuri, Sravanthi ^a   Flynn, Nicholas ^a   Neely, Brian J ^a   Ramsey, Joshua D ^a  

^a Oklahoma State University   (United States)

Author keywords

Adenoviral vectors; Cell penetrating peptides; Coxsackie adenovirus receptor (CAR); Gene delivery; Membrane translocation; Physicochemical properties; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ARGININE; CELL PENETRATING PEPTIDE; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; LIPOSOME; PENETRATIN; POLYARGININE;

ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; INCUBATION TIME; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN LOCALIZATION; VIRAL GENE DELIVERY SYSTEM; ZETA POTENTIAL;

EID: 84877927795     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23556     Document Type: Article

References (44)

1. Benihoud K, Yeh P, Perricaudet M. 1999. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 10(5):440-447.
2. Mizuguchi H, Hayakawa T. 2004. Targeted adenovirus vectors. Hum Gene Ther 15(11):1034-1044.
3. Campos SK, Barry MA. 2007. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 7(3):189-204.
4. Bergelson JM, Cunningham JA, Droguett G, KurtJones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275(5304):1320-1323.
5. Wickham TJ. 2000. Targeting adenovirus. Gene therapy 7(2):110-114.
6. Kreppel F, Gackowski J, Schmidt E, Kochanek S. 2005. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther 12(1):107-117.
7. Ogawara K, Rots MG, Kok RJ, Moorlag HE, Van Loenen AM, Meijer DK, Haisma HJ, Molema G. 2004. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 15(5):433-443.
8. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, Yeh P. 1999. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 73(6):5156-5161.
9. Kaplan JM, Pennington SE, St George JA, Woodworth LA, Fasbender A, Marshall J, Cheng SH, Wadsworth SC, Gregory RJ, Smith AE. 1998. Potentiation of gene transfer to the mouse lung by complexes of adenovirus vector and polycations improves therapeutic potential. Hum Gene Ther 9(10):1469-1479.
10. Fonseca SB, Pereira MP, Kelley SO. 2009. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 61(11):953-964.
11. Meade BR, Dowdy SF. 2008. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev 60(4-5):530-536.
12. Ignatovich IA, Dizhe EB, Pavlotskaya AV, Akifiev BN, Burov SV, Orlov SV, Perevozchikov AP. 2003. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J Biol Chem 278(43):42625-42636.
13. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R. 2000. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18(4):410-414.
14. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. 2001. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A 98(15):8786-8791.
15. Tseng YL, Liu JJ, Hong RL. 2002. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: A kinetic and efficacy study. Mol Pharmacol 62(4):864-872.
16. Mae M, Langel U. 2006. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol 6(5):509-514.
17. Snyder EL, Saenz CC, Denicourt C, Meade BR, Cui XS, Kaplan LM, Dowdy SF. 2005. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res 65(23):10646-10650.
18. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, Giordano FJ, Sessa WC. 2003. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med 9(3):357-362.
19. Lehmusvaara S, Rautsi O, Hakkarainen T, Wahifors J. 2006. Utility of cell-permeable peptides for enhancement of virus-mediated gene transfer to human tumor cells. Biotechniques 40(5):573-574, 576.
20. Morris MC, Depollier J, Mery J, Heitz F, Divita G. 2001. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19(12):1173-1176.
21. Gros E, Deshayes S, Morris MC, Aldrian-Herrada G, Depollier J, Heitz F, Divita G. 2006. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta 1758(3):384-393.
22. GenScript. Peptide property calculator. Accessed at: https://www.genscript.com/ssl-bin/site2/peptide_calculation.cgi. (accessed November 11, 2012).
23. Yang Y, Wang X, Dai W. 2006. Human Sgo1 is an excellent target for induction of apoptosis of transformed cells. Cell Cycle 5(8):896-901.
24. Pappalardo JS, Quattrocchi V, Langellotti C, Di Giacomo S, Gnazzo V, Olivera V, Calamante G, Zamorano PI, Levchenko TS, Torchilin VP. 2009. Improved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes. J Control Release 134(1):41-46.
25. Crombez L, Aldrian-Herrada G, Konate K, Nguyen QN, McMaster GK, Brasseur R, Heitz F, Divita G. 2009. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 17(1):95-103.
26. Sharma S, Miyanohara A, Friedmann T. 2000. Separable mechanisms of attachment and cell uptake during retrovirus infection. J Virol 74(22):10790-10795.
27. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. 2004. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J 377:159-169.
28. Eto Y, Yoshioka Y, Asavatanabodee R, Kida S, Maeda M, Mukai Y, Mizuguchi H, Kawasaki K, Okada N, Nakagawa S. 2009. Transduction of adenovirus vectors modified with cell-penetrating peptides. Peptides 30(8):1548-1552.
29. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. 2007. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8(7):848-866.
30. Zorko M, Langel U. 2005. Cell-penetrating peptides: Mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 57(4):529-545.
31. Patel LN, Zaro JL, Shen WC. 2007. Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives. Pharm Res 24(11):1977-1992.
32. Ziegler A, Nervi P, Durrenberger M, Seelig J. 2005. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: Optical, biophysical, and metabolic evidence. Biochemistry 44(1):138-148.
33. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. 2003. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 278(33):31192-31201.
34. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B. 2003. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278(1):585-590.
35. Magzoub M, Graslund A. 2004. Cell-penetrating peptides: Small from inception to application. Q Rev Biophys 37(2):147-195.
36. Lundberg M, Wikstrom S, Johansson M. 2003. Cell surface adherence and endocytosis of protein transduction domains. Mol Ther 8(1):143-150.
37. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K. 2003. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 278(37):35109-35114.
38. Magzoub M, Graslund A. 2004. Cell-penetrating peptides: [corrected] From inception to application. Q Rev Biophys 37(2):147-195.
39. Deshayes S, Morris MC, Divita G, Heitz F. 2005. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell Mol Life Sci 62(16):1839-1849.
40. Poon GM, Gariepy J. 2007. Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells. Biochem Soc Trans 35(Pt 4):788-793.
41. Fischer D, Bieber T, Li YX, Elsasser HP, Kissel T. 1999. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: Effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 16(8):1273-1279.
42. Saalik P, Elmquist A, Hansen M, Padari K, Saar K, Viht K, Langel V, Pooga M. 2004. Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjug Chem 15(6):1246-1253.
43. Kosuge M, Takeuchi T, Nakase I, Jones AT, Futaki S. 2008. Cellular internalization and distribution of arginine-rich peptides as a function of extracellular peptide concentration, serum, and plasma membrane associated proteoglycans. Bioconjug Chem 19(3):656-664.
44. Kwoh DY, Coffin CC, Lollo CP, Jovenal J, Banaszczyk MG, Mullen P, Phillips A, Amini A, Fabrycki J, Bartholomew RM, Brostoff SW, Carlo DJ. 1999. Stabilization of poly-l-lysine/DNA polyplexes for in vivo gene delivery to the liver. Biochim Biophys Acta 1444(2):171-190.